IP Library › Granted Patent US 12667610
Granted Patent B2
US 12667610 · App. 17/686,606 · Granted Jun 30, 2026

Vaccine composition comprising recombinant protein of

Inventors: Dong Chan Moon (Gyeongsangbuk-do, KR); Suk Kyung Lim (Gyeongsangbuk-do, KR); Keum Chan Jang (Gyeonggi-do, KR); Suk Chan Jung (Gyeongsangbuk-do, KR); Hee Soo Lee (Gyeonggi-do, KR); Bang Hun Hyun (Gyeongsangbuk-do, KR); Hyang Mi Nam (Gyeongsangbuk-do, KR); Heui Jin Kim (Gyeongsangbuk-do, KR); Keun Seok Seo (Starkville, MS)
Assignees: REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY); Mississippi State University
A61K39/085A61K39/39A61P31/04C07K14/31A61K2039/55505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667610
App. No.
17/686,606
Granted
Jun 30, 2026
Kind
B2
Abstract

The present invention relates to a vaccine composition comprising a Staphylococcus aureus attenuated enterotoxin protein and cytotoxin protein, and more particularly to a Staphylococcus aureus enterotoxin protein, a Staphylococcus aureus cytotoxin protein, a vaccine composition for prevention of bovine mastitis, comprising the Staphylococcus aureus enterotoxin protein and Staphylococcus aureus cytotoxin protein and a method for preventing bovine mastitis comprising administering the vaccine composition to a bovine. The Staphylococcus aureus enterotoxin protein, the Staphylococcus aureus cytotoxin protein according to the present invention, and the vaccine composition comprising the proteins as an antigen can be used so that even vaccines comprising several antigens rather than all kinds of antigens show the excellent effects of prevention and treatment of bovine mastitis against all kinds of Staphylococcus aureus enterotoxin and cytotoxin having high incidence in Korea, thereby being more economically used for industrial purposes. Further, the vaccine composition for prevention of bovine mastitis, comprising the Staphylococcus aureus enterotoxin protein and Staphylococcus aureus cytotoxin protein according to the present invention has an excellent safety and bovine mastitis prevention and treatment effect even in the high CFU Staphylococcus aureus challenge test so that the composition can be variously utilized in Staphylococcus aureus vaccine and prevention related fields in future.

Claims (8)

1 . A recombinant vector comprising a gene encoding a protein comprising an amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10.

2 . The recombinant vector according to claim 1 , wherein the amino acid sequence represented by SEQ ID NO: 2 is encoded by a nucleotide sequence represented by SEQ ID NO: 1.

3 . A transformant having the recombinant vector according to claim 1 inserted therein.

4 . The transformant according to claim 3 , wherein the transformant is a Staphylococcus aureus RN4220 strain or an Escherichia coli BL21 strain.

5 . The recombinant vector according to claim 1 , wherein the amino acid sequence represented by SEQ ID NO: 4 is encoded by a nucleotide sequence represented by SEQ ID NO: 3.

6 . The recombinant vector according to claim 1 , wherein the amino acid sequence represented by SEQ ID NO: 6 is encoded by a nucleotide sequence represented by SEQ ID NO: 5.

7 . The recombinant vector according to claim 1 , wherein the amino acid sequence represented by SEQ ID NO: 8 is encoded by a nucleotide sequence represented by SEQ ID NO: 7.

8 . The recombinant vector according to claim 1 , wherein the amino acid sequence represented by SEQ ID NO: 10 is encoded by a nucleotide sequence represented by SEQ ID NO: 9.